Centessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Chardan Capital

Stock analysts at Chardan Capital initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $30.00 price target on the stock. Chardan Capital's price objective would indicate a potential upside of 138.47% from the stock's previous close.

Several other equities research analysts have also issued reports on the stock. Guggenheim reaffirmed a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Morgan Stanley restated an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They issued an "overweight" rating and a $38.00 price target on the stock. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $27.00.

Centessa Pharmaceuticals Stock Down 4.3%

CNTA stock traded down $0.57 during mid-day trading on Thursday, hitting $12.58. 212,544 shares of the company were exchanged, compared to its average volume of 624,447. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals has a 1-year low of $7.75 and a 1-year high of $19.09. The firm has a market cap of $1.68 billion, a P/E ratio of -8.22 and a beta of 1.53. The firm's 50 day simple moving average is $13.79 and its 200 day simple moving average is $15.66.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. On average, sell-side analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Buying and Selling

In other news, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $16.18, for a total value of $97,080.00. Following the sale, the general counsel now directly owns 105,386 shares of the company's stock, valued at approximately $1,705,145.48. This represents a 5.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the completion of the transaction, the chief executive officer now owns 331,017 shares in the company, valued at approximately $5,273,100.81. This trade represents a 14.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 171,398 shares of company stock valued at $2,697,422. 11.59% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in Centessa Pharmaceuticals by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock valued at $959,000 after acquiring an additional 660 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after purchasing an additional 865 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $31,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Centessa Pharmaceuticals by 15,209.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after purchasing an additional 3,194 shares during the period. Finally, Barclays PLC boosted its stake in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after purchasing an additional 4,952 shares during the period. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.